CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Develop an understanding of validated biomarkers of response in CRC, such as RAS mutations, microsatellite instability (MSI)/mismatch repair (MMR) deficiency, HER2 overexpression and BRAF V600E mutations, and consider the implications for molecular testing and clinical care.
  • Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering various clinical and biological factors such as age, performance status, disease stage, MSI/MMR status and the potential relevance of molecular residual disease.
  • Formulate a plan to guide the selection and sequencing of therapy for patients with metastatic CRC (mCRC), accounting for tumor sidedness, biomarker profile, prior systemic therapy, symptomatology and personal goals of treatment.
  • Evaluate the biological rationale for the use of immune checkpoint inhibitors in the treatment of MSI-high/MMR-deficient localized or advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed therapy recommendations.
  • Appreciate published and emerging research documenting the efficacy of BRAF/EGFR inhibition for newly diagnosed or relapsed/refractory mCRC with a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into patient care.
  • Recognize available data with HER2-targeted therapies for HER2-positive mCRC, and consider the current role of FDA-approved approaches.
  • Apply available research to optimize the selection and sequencing of therapy for patients with mCRC and a KRAS G12C mutation, considering the implications of recent clinical trial findings and regulatory actions.
  • Recall ongoing trials evaluating novel biomarker-directed agents and strategies for CRC, and use this information to appropriately refer patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Arvind Dasari, MD, MS
  Professor
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Bristol Myers Squibb, Exelixis Inc, Illumina, Lantheus, Personalis, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Eisai Inc, Enterome, Guardant Health, Hutchison MediPharma, Natera Inc, NeoGenomics, Personalis, Taiho Oncology Inc, Xencor.
  
  Van K Morris, MD
  Associate Professor
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committees: AmMax Bio, Bristol Myers Squibb, Incyte Corporation, Pfizer Inc, Scandion Oncology; Contracted Research: AmMax Bio, Bicara Therapeutics, BioNTech SE, Bristol Myers Squibb, Pfizer Inc.
  
  Jenny Seligmann, MBChB, PhD
  Professor of Gastrointestinal Cancer
  University of Leeds
  Leeds, United Kingdom
  
  Advisory Committees: Bristol Myers Squibb, GSK, Merck Serono, Nanobiotix, Sanofi, Servier Pharmaceuticals LLC; Contracted Research: GSK, Merck Serono, Pierre Fabre, Roche Diagnostics; Data and Safety Monitoring Boards/Committees: GSK; Speakers Bureaus: Bayer HealthCare Pharmaceuticals, GSK, Merck Serono, Servier Pharmaceuticals LLC.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospitals Leuven
  Leuven, Belgium
  
  Advisory Committees: AbbVie Inc, Agenus Inc, ALX Oncology, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Cantargia AB (CANFOUR trial), Daiichi Sankyo Inc, Debiopharm, Eisai Inc, ElmediX, Galapagos NV, GSK, Hookipa Pharma Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Mirati Therapeutics Inc, MSD, Nordic Pharma, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Simcere, Taiho Oncology Inc, Takeda Pharmaceutical Company Limited, Terumo Medical Corporation; Nonrelevant Financial Relationships: Bexon Clinical Consulting.
  
  MODERATOR
  Christopher Lieu, MD
  Professor of Medicine
  Associate Director for Clinical Research
  Co-Director, GI Medical Oncology
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreements: Amgen Inc, Pfizer Inc; Contracted Research: Genentech, a member of the Roche Group, Sanofi.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from GSK, Natera Inc, and Pfizer Inc.
  
  Release date: February 2025
  Expiration date: February 2026